

April 30, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001

BSE Scrip Code: 506943 Stock Symbol: JBCHEPHARM

Dear Sir,

Sub.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), this is to inform that the Company has received a favorable order from Office of The Commissioner (Appeals), GST & Central Excise, Vadodara

The relevant information in the format prescribed by SEBI vide its circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is as under:

Name of the authority	The Commissioner (Appeals), GST & Central Excise, Vadodara
Nature and details of the action(s) taken, initiated or order(s) passed	Demand of ~ Rs. 3.61 crores set aside in respect of Cenvat Credit availed by the Company in FY 2013-14.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	30 <sup>th</sup> April, 2024



Details of the violation(s)/contravention(s) committed or alleged to be committed	Demand of Rs. 3.61 crores set aside by the Commissioner (Appeals)
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Company has received a favorable order in respect of Appeal filed against the order passed by Joint Commissioner.

We request you to take the above on record.

Thanking you,

Yours faithfully, For J.B. Chemicals & Pharmaceuticals Ltd.

Sandeep Phadnis
Vice President – Secretarial
& Company Secretary